Please Subscribe to get a daily link to Pat's blog via email


Your privacy is important to us. We will never spam you and keep your personal data secure.

kinase inhibitor

Home/Tag:kinase inhibitor
30 11, 2010

Pfizer To Present Multiple Myeloma Related Phase 1 Results Evaluating PD0332991 At ASH

Tags: , , , |0 Comments

While I was researching my pre-ASH article on our Help With site this morning (that is where I post non-myeloma related cancer news from large oncology conferences like ASH and ASCO), I found this interesting tidbit burried deep in one of Pfizer's press releases:A Phase 1 trial evaluating PD 0332991 in combination with bortezomib

14 11, 2010

Experimental Ovarian Cancer Drug, ENMD-2076, May Work Against Acute Myeloid Leukemia & Multiple Myeloma Too!

Tags: , , , , |0 Comments

Here is another pre-ASH press release from Phase 1 Data in Hematological Studies to be Presented at ASHENMD-2076 Multiple Myeloma and Leukemia Abstracts to be Published in BloodROCKVILLE, Md., Nov. 9, 2010 /PRNewswire-FirstCall:EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today announced presentations for its Phase 2

18 08, 2010

Promising Research Results Using Kinase Inhibitors Continue To Roll In

Tags: , , |0 Comments

Here is a research abstract, published in Blood, testing the viability of one of the new kinase inhibitors:Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor Bao Hoang1, Patrick Frost1, Yijiang Shi1, Eileen Belanger1, Angelica Benavides1, Gholam Pezeshkpour2, Susanna Cappia3, Tommasina Guglielmelli3, Joseph Gera1 and Alan Lichtenstein1,* 1 Division of Hematology Oncology, UCLA-Greater

15 08, 2010

New Phase 2 Study In England Features Kinase Inhibitor, AT7519, For Patients With Relapsed Or Refractory Multiple Myeloma

Tags: , , , , , |2 Comments

The Journal of New England Technology ran this article Friday:MMRC joins UK biotech in start of multiple myeloma trialA Phase 2 clinical trial of a treatment for relapsed or refractory multiple myeloma has launched, led by U.K.-based Astex Therapeutics Ltd. and funded by Norwalk, Conn.-based Multiple Myeloma Research Consortium (MMRC). Noopur Raje, of the Massachusetts

15 07, 2010

New British Anti-Myeloma Drug Study Shows Promise

Tags: , |0 Comments

Here is a link to a British study abstract about another new, anti-myeloma drug:EntreMed’s ENMD-2076 Demonstrates Significant Anti-Cancer Activity in Multiple Myeloma Preclinical Models.The study results were published in the British Journal of Haematology.ENMD-2076 is another variation of a kinase inhibitor.  Lots of research going on worldwide using kinase inhibitors against multiple myeloma.  Hopefully some